Marks Kite News Today

KITE'S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL)

September 7, 2022

KITE&rsquo;S&nbsp; CAR&nbsp; T-CELL&nbsp; THERAPY&nbsp; TECARTUS&reg;&nbsp; (BREXUCABTAGENE&nbsp; AUTOLEUCEL)&nbsp; GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF&nbsp; RELAPSED&nbsp; OR&nbsp; REFRACTORY&nbsp; ACUTE&nbsp; LYMPHOBLASTIC&nbsp; LEUKAEMIA&nbsp; (r/r ALL)&nbsp;-- Approval Marks Kite&rsquo;...

United States Santa Monica United Kingdom Foster City Christi Shaw Brexucabtagene Autoleucel

Source: pharmiweb.com

Gilead Sciences, Inc.: Kite's CAR T-cell Therapy Tecartus Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

September 6, 2022

-- Approval Marks Kite's Fourth Indication in Europe for its Two Cell Therapies and First in Leukemia -- -- Overall Complete Remission of 71% and a Median Overall Survival of More Than Two Years

Navigation

Marks Kite News Today

KITE'S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL)

Gilead Sciences, Inc.: Kite's CAR T-cell Therapy Tecartus Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

Explore More Categories

Navigation

Marks Kite News Today

KITE'S CAR T-CELL THERAPY TECARTUS&#xAE; (BREXUCABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL)

Gilead Sciences, Inc.: Kite's CAR T-cell Therapy Tecartus Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

Explore More Categories

KITE'S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL)